Authors:
Schaefer R, Donaldson L, Leus M, Osakwe CE, Chimukangara B, Dalal S, Duerr A, Gao F, Glidden DV, Grinsztejn B, Justman J, Kumwenda G, Laeyendecker O, Lee HY, Maldarelli F, Mayer KH, Murray J, Parekh BS, Rice B, Robertson MN, Saito S, Vannappagari V, Warren M, Zeballos D, Zinserling J, Miller V.
Abstract:
Twelve years ago, in 2012, the US Food and Drug Administration (FDA) approved oral tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) as pre-exposure prophylaxis (PrEP) for HIV prevention. In 2015, the World Health Organization (WHO) recommended offering oral PrEP to all people at substantial HIV risk. In 2023, there were 3.5 million PrEP users globally [
1], up from 600,000 users in 2019 [
2]. However, progress varies significantly across regions, countries, and populations, and further increases are needed to meet the 21.2 million PrEP user target by the end of 2025 [
1]. Only Eastern and Southern Africa is on track to meet its target of 3.6 million users (2.4 million in 2023). Furthermore, in 2023, 1.3 million people acquired HIV globally [
1], underscoring the ongoing need to improve access to prevention options and develop new products that align with user needs and preferences. In this article, we argue that collaboration between diverse stakeholders is necessary to address critical issues in the HIV response and advance global health (
Box 1).